IL161744A0 - Combination therapy comprising zd6474 and a taxane - Google Patents

Combination therapy comprising zd6474 and a taxane

Info

Publication number
IL161744A0
IL161744A0 IL16174402A IL16174402A IL161744A0 IL 161744 A0 IL161744 A0 IL 161744A0 IL 16174402 A IL16174402 A IL 16174402A IL 16174402 A IL16174402 A IL 16174402A IL 161744 A0 IL161744 A0 IL 161744A0
Authority
IL
Israel
Prior art keywords
taxane
combination therapy
therapy
combination
Prior art date
Application number
IL16174402A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL161744A0 publication Critical patent/IL161744A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16174402A 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane IL161744A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (1)

Publication Number Publication Date
IL161744A0 true IL161744A0 (en) 2005-11-20

Family

ID=9925430

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16174402A IL161744A0 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
IL161744A IL161744A (en) 2001-11-08 2004-05-03 Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161744A IL161744A (en) 2001-11-08 2004-05-03 Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds

Country Status (23)

Country Link
US (2) US20050043395A1 (da)
EP (1) EP1446124B1 (da)
JP (1) JP4694127B2 (da)
KR (1) KR100959607B1 (da)
CN (1) CN1298328C (da)
AR (1) AR037346A1 (da)
AT (1) ATE335488T1 (da)
AU (1) AU2002337382B2 (da)
BR (1) BR0213906A (da)
CA (1) CA2464758C (da)
CY (1) CY1106259T1 (da)
DE (1) DE60213845T2 (da)
DK (1) DK1446124T3 (da)
ES (1) ES2269769T3 (da)
GB (1) GB0126879D0 (da)
HK (1) HK1068546A1 (da)
IL (2) IL161744A0 (da)
MX (1) MXPA04004355A (da)
NO (1) NO328048B1 (da)
NZ (1) NZ532525A (da)
PT (1) PT1446124E (da)
WO (1) WO2003039551A1 (da)
ZA (1) ZA200403455B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU779695B2 (en) * 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
RU2362774C1 (ru) * 2002-02-01 2009-07-27 Астразенека Аб Хиназолиновые соединения
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR101089462B1 (ko) 2002-11-04 2011-12-07 아스트라제네카 아베 Ｓｒｃ 티로신 키나제 억제제로서의 퀴나졸린 유도체
NZ541297A (en) * 2003-02-13 2008-03-28 Astrazeneca Ab Combination therapy of ZD6474 with 5-FU or/and CPT-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
KR20120093411A (ko) * 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP2277595A3 (en) * 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PT1971338E (pt) * 2005-12-22 2011-05-09 Astrazeneca Ab Combina??o de zd6474 e pemetrexed
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
JP2000510460A (ja) * 1996-04-26 2000-08-15 マゲイニン・ファーマシューティカルズ・インコーポレーテッド スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
AU768027B2 (en) * 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
EP1185559A2 (en) * 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
UA72946C2 (uk) * 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
JP2006502132A (ja) * 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ541297A (en) * 2003-02-13 2008-03-28 Astrazeneca Ab Combination therapy of ZD6474 with 5-FU or/and CPT-11
KR20120093411A (ko) * 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
PT1971338E (pt) * 2005-12-22 2011-05-09 Astrazeneca Ab Combina??o de zd6474 e pemetrexed
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
NO328048B1 (no) 2009-11-16
EP1446124B1 (en) 2006-08-09
NO20042365L (no) 2004-06-07
PT1446124E (pt) 2006-12-29
KR20050043779A (ko) 2005-05-11
NZ532525A (en) 2006-11-30
CN1298328C (zh) 2007-02-07
IL161744A (en) 2012-01-31
AU2002337382B2 (en) 2008-06-12
CA2464758C (en) 2010-09-28
KR100959607B1 (ko) 2010-05-27
DE60213845T2 (de) 2007-03-29
US20050043395A1 (en) 2005-02-24
JP4694127B2 (ja) 2011-06-08
DK1446124T3 (da) 2006-11-13
CY1106259T1 (el) 2011-06-08
US20120252827A1 (en) 2012-10-04
GB0126879D0 (en) 2002-01-02
WO2003039551A1 (en) 2003-05-15
DE60213845D1 (de) 2006-09-21
JP2005511597A (ja) 2005-04-28
AR037346A1 (es) 2004-11-03
CN1612738A (zh) 2005-05-04
ES2269769T3 (es) 2007-04-01
HK1068546A1 (en) 2005-04-29
ATE335488T1 (de) 2006-09-15
MXPA04004355A (es) 2004-08-11
BR0213906A (pt) 2004-08-31
EP1446124A1 (en) 2004-08-18
CA2464758A1 (en) 2003-05-15
ZA200403455B (en) 2005-08-29

Similar Documents

Publication Publication Date Title
HK1068546A1 (en) Combination therapy comprising zd6474 and taxane
GB0111872D0 (en) Therapeutic agents and methods
EP1463438A4 (en) ENDOMURAL THERAPY
PL370563A1 (en) Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
GB0119025D0 (en) Compounds and their therapeutic use
GB0108485D0 (en) Combination therapy
GB0101933D0 (en) Therapy
SI1446124T1 (sl) Kombinacijska terapija, ki obsega ZD6474 in taksan
HU0200253D0 (en) Combination therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
GB0128122D0 (en) Therapeutic use
GB0123991D0 (en) New therapeutic use
GB0128512D0 (en) Compounds and their therapeutic use
GB0201615D0 (en) Compounds and their therapeutic use
GB0124029D0 (en) Combination therapy
GB0108816D0 (en) Therapy
GB0108817D0 (en) Therapy
GB0108821D0 (en) Therapy
GB0130678D0 (en) Medicaments and novel compounds
GB0130679D0 (en) Medicaments and novel compounds
GB0130785D0 (en) Medicaments and novel compounds
GB0128128D0 (en) Therapeutic use
GB0128089D0 (en) Therapeutic use
GB0128126D0 (en) Therapeutic use